CoChat

A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study

Open access
Kashiwagi, A., Takahashi, H., Ishikawa, H., Yoshida, S., Kazuta, K., Utsuno, A., Ueyama, E. · 2015 · Diabetes, Obesity and Metabolism
Cited by 116

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Aims: To assess the effects of renal impairment (RI) on the efficacy and safety of ipragliflozin in patients with type 2 diabetes mellitus (T2DM). Methods: A cohort of Japanese patients with T2DM and mild to moderate RI and poor glycaemic control, despite diet/exercise therapy alone or diet/exercise therapy in combination with an oral hypoglycaemic agent (an α‐glucosidase inhibitor, a sulfonylurea, or pioglitazone), were randomized in a double‐blind manner to 50 mg ipragliflozin or placebo once daily for 24 weeks. The patients continued open‐label ipragliflozin for a 28‐week extension period (total treatment duration: 52 weeks). Results: Ipragliflozin significantly decreased glycated haemoglobin (HbA1c) and fasting plasma glucose ( FPG ) levels and body weight from baseline to week 24 (last observation carried forward) compared with placebo in all patients with RI . The decreases in HbA1c and FPG levels were statistically significant in patients with mild RI , but not in patients with moderate RI . Ipragliflozin significantly reduced body weight in both RI groups. The improvements in glycaemic control were maintained in the 28‐week extension period. Ipragliflozin was associated with no clinically significant safety concerns, and its safety profiles were not influenced by the severity of RI . Conclusions: Ipragliflozin significantly improved glycaemic control and body weight in patients with T2DM with mild RI , but did not improve glycaemic control in patients with moderate RI . Ipragliflozin is a valid treatment option for patients with mild RI but not those with moderate RI .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12403

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 19

  1. 10.1152/ajprenal.2001.280.1.F10 · DOI · Paper page
  2. 10.1038/ki.2009.87 · DOI · Paper page
  3. Krook A, 1997, Improved glucose tolerance restores insulin‐stimulated Akt kinase activity and glucose transport in skeletal muscle from diabetic Goto‐Kakizaki rats, Diabetes, 46, 2110, 10.2337/diab.46.12.2110 · DOI · Paper page
  4. 10.1254/jphs.12089FP · DOI
  5. 10.1007/s00210-011-0713-z · DOI
  6. 10.1111/jdi.12156 · DOI · Paper page
  7. 10.1016/j.jdiacomp.2012.11.005 · DOI
  8. 10.1111/dom.12038 · DOI · Paper page
  9. 10.1007/s13340-012-0069-8 · DOI · Paper page
  10. 10.1053/j.ajkd.2008.12.034 · DOI · Paper page
  11. 10.1007/s13340‐014‐0184‐9 · DOI
  12. 10.1111/dom.12331 · DOI · Paper page
  13. 10.1007/s13340-014-0182-y · DOI
  14. 10.1111/dom.12090 · DOI · Paper page
  15. 10.2337/dc12-1503 · DOI · Paper page
  16. 10.1007/s13340-014-0164-0 · DOI
  17. 10.1016/j.diabres.2014.07.020 · DOI
  18. 10.1111/j.1463-1326.2012.01630.x · DOI · Paper page
  19. 10.2337/dc11-1926 · DOI · Paper page

Cited by

See all 116

Metadata

Authors
Kashiwagi, A., Takahashi, H., Ishikawa, H., Yoshida, S., Kazuta, K., Utsuno, A., & Ueyama, E.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2015-01-21
Volume
17
Issue
2
Pages
152-160
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1557519555
Cited by
116
References
3
FWCI
6.70
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.